Oxford BioDynamics appoints new CEO to drive growth

Dr Jon Burrows CEO Oxford Biodynamics

Oxford BioDynamics, the a biotechnology company focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitchTM, has appointed Dr Jon Burrows as Group Chief Executive Officer, effective 23 March 2020. Dr Burrows brings over 25 years of industry experience with an established track record in oncology and personalised medicine within big pharma, biotech and molecular diagnostics companies. Jon will lead the Company from a base in Maryland, USA, a location which will help OBD to further expand its US presence.

Jon joins OBD from Oncology Partners, a consulting and clinical advisory firm focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies, which he co-founded. Previously Jon was President and CEO of OncoPlex Diagnostics, a leader in clinical proteomics for oncology. Under Jon’s leadership OncoPlex was transformed from a private, pre-revenue stage company into a thriving clinical diagnostics business with marketed products, which was ultimately acquired by NantOmics in May 2015. From 2007 to 2009, he was Director of Business Development and Interim Head of the Translational Diagnostics Business Unit at Ventana Medical Systems, and subsequently Director of Pharma Operations at Roche, following the $3.4 billion acquisition of Ventana Medical Systems by Roche in 2008. His early career was in oncology drug development and the development of molecular diagnostics for precision medicine.